Leerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10
Leerink Partners analyst Daniel Clark initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Market Perform rating and announces Price Target of $10.
A big investment research company started watching Phathom Pharmaceuticals closely and said the stock price should stay around $10. This is their neutral view—neither super exciting nor worrying—so watch how the company's medicines do in the real world.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.